{"id":"nadide","rwe":[{"pmid":"37396659","year":"2023","title":"Identifying potential drug-target interactions based on ensemble deep learning.","finding":"","journal":"Frontiers in aging neuroscience","studyType":"Clinical Study"},{"pmid":"35789829","year":"2022","title":"Drug repurposing against main protease and RNA-dependent RNA polymerase of SARS-CoV-2 using molecular docking, MM-GBSA calculations and molecular dynamics.","finding":"","journal":"Structural chemistry","studyType":"Clinical Study"},{"pmid":"34601658","year":"2021","title":"Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.","finding":"","journal":"Journal of molecular modeling","studyType":"Clinical Study"},{"pmid":"33352458","year":"2021","title":"Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study.","finding":"","journal":"Computers in biology and medicine","studyType":"Clinical Study"},{"pmid":"480166","year":"1979","title":"Improved spectrophotometric determination of glycerol and its comparison with an enzymatic method.","finding":"","journal":"Journal of pharmaceutical sciences","studyType":"Clinical Study"}],"_fda":{"id":"ed806a9b-af06-d713-e053-2a95a90a9730","set_id":"45ad3f03-0ee8-438f-81e7-3ca772022c98","openfda":{"nui":["N0000193618","M0001797"],"upc":["0317089304180"],"unii":["8ID597Z82X","73Y7P0K73Y","PQ6CK8PD0R","L7A49804ZQ","K73E24S6X9","T7J046YI2B","I0IO929019","4R7X1O2820","993QHL78E6","0U46U6E8UK","V7FWP1D62O","459AG36T1B","P4A66LQ3QJ","6CA025Y4FG","W6J1279A6K","41YPU4MMCA","70FD1KFU70","398IYQ16YV","63O327782Q","73ECW5WG2F","W61ME6Q717","2KBE35NE8S","C8CV8867O8","118OYG6W3H","2510RH3I89","6IO182RP7A","6Z25C35927"],"route":["ORAL"],"spl_id":["ed806a9b-af06-d713-e053-2a95a90a9730"],"brand_name":["GUNA-ARTHRO"],"spl_set_id":["45ad3f03-0ee8-438f-81e7-3ca772022c98"],"package_ndc":["17089-304-18"],"product_ndc":["17089-304"],"generic_name":[".ALPHA.-KETOGLUTARIC ACID - ALPHA LIPOIC ACID - ASCORBIC ACID - BARIUM OXALOSUCCINATE - BLACK COHOSH - BRYONIA ALBA ROOT - CALCITONIN HUMAN - CHLORINE - COLCHICUM AUTUMNALE BULB - NADIDE -"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Ascorbic Acid [CS]"],"substance_name":[".ALPHA.-KETOGLUTARIC ACID",".ALPHA.-LIPOIC ACID","ASCORBIC ACID","BARIUM OXALOSUCCINATE","BLACK COHOSH","BRYONIA ALBA ROOT","CALCITONIN HUMAN","CHLORINE","COLCHICUM AUTUMNALE BULB","NADIDE","NERVE GROWTH FACTOR","PRASTERONE","QUINHYDRONE","SODIUM DIETHYL OXALACETATE","SOLANUM DULCAMARA FLOWER","STRONTIUM CARBONATE","SULFUR","SUS SCROFA ADRENAL GLAND","SUS SCROFA ARTERY","SUS SCROFA CARTILAGE","SUS SCROFA CONJUNCTIVA","SUS SCROFA PARATHYROID GLAND","SUS SCROFA PLACENTA","SUS SCROFA UMBILICAL CORD","SUS SCROFA VEIN","TOXICODENDRON PUBESCENS LEAF","VELAFERMIN"],"pharm_class_epc":["Vitamin C [EPC]"],"manufacturer_name":["Guna spa"],"is_original_packager":[true]},"purpose":["USES Temporary relief of minor arthritis symptoms such as: Joint stiffness Joint pain"],"version":"6","warnings":["WARNINGS Stop use and ask doctor if symptoms persist more than 5 days. If pregnant or breast-feeding ask a health professional before use. Keep out of reach of children . In case of overdose, get medical help or contact a Poison Control Center right away. Contains ethyl alcohol 30%"],"questions":["QUESTIONS Questions?: info@gunainc.com Tel. (484) 223-3500"],"effective_time":"20221115","active_ingredient":["ACTIVE INGREDIENTS/PURPOSE ALPHA-KETOGLUTARICUM ACID 3X SUPPORTS CELLULAR RESPIRATION ALPHA-LIPOIC ACID 3X ANTIOXIDANT ARTERY 6X PROMOTES METABOLISM ASCORBIC ACID 3X ANTIOXIDANT BARIUM OXALOSUCCINATE 3X SUPPORTS CELLULAR RESPIRATION BRYONIA ALBA 6X, 8X, 12X ANTI-INFLAMMATORY CALCITONIN 6X PROMOTES MINERALIZATION CARTILAGO 6X SUPPORTS TISSUE REPAIR CHLORINUM 6X STRENGTHENS IMMUNE RESPONSE CIMICIFUGA RACEMOSA 6X, 8X, 12X PAIN RELIEF COLCHICUM AUTUMNALE 6X, 8X, 12X ANTIOXIDANT CONJUNCTIVA TISSUE 6X PROMOTES TISSUE REPAIR DEHYDROEPIANDROSTERONE 6X PROMOTES TISSUE REPAIR DULCAMARA 6X, 8X, 12X ANTI-INFLAMMATORY FIBROBLAST GROWTH FACTOR 4C PROMOTES TISSUE REPAIR FUNICULUS UMBILICALIS 6X SUPPORTS TISSUE REPAIR GLANDULA SUPRARENALIS 6X ANTI-INFLAMMATORY NADIDUM 3X PROMOTES CELL METABOLISM NATRUM OXALACETICUM 3X ANTIOXIDANT NERVOUS GROWTH FACTOR 4C PAIN RELIEF PARATHYROID GLAND 6X METABOLIC SUPPORT PLACENTA TOTALIS 6X REVITALIZING QUINHYDRONE 3X ANTIOXIDANT RHUS TOXICODENDRON 6X, 8X, 12X NERVE PAIN RELIEF STRONTIUM CARBONICUM 6X, 8X, 12X PAIN RELIEF SULPHUR 3X SENSITIVE SKIN VEIN 6X PROMOTES METABOLISM"],"inactive_ingredient":["Inactive ingredient: Ethyl alcohol 30%."],"indications_and_usage":["Take 15 minutes before meals"],"dosage_and_administration":["DIRECTIONS Adults and children 12 years and older 20 drops in a little water 2 times per day Children between 12 years and 6 years of age 10 drops in a little water 2 times per day Children under 6 years 5 drops in a little water 2 times per day"],"spl_product_data_elements":["GUNA-ARTHRO .ALPHA.-KETOGLUTARIC ACID - ALPHA LIPOIC ACID - ASCORBIC ACID - BARIUM OXALOSUCCINATE - BLACK COHOSH - BRYONIA ALBA ROOT - CALCITONIN HUMAN - CHLORINE - COLCHICUM AUTUMNALE BULB - NADIDE - SUS SCROFA ARTERY SUS SCROFA ARTERY ASCORBIC ACID ASCORBIC ACID BARIUM OXALOSUCCINATE BARIUM CATION BRYONIA ALBA ROOT BRYONIA ALBA ROOT CALCITONIN HUMAN CALCITONIN HUMAN SUS SCROFA CARTILAGE SUS SCROFA CARTILAGE CHLORINE CHLORINE BLACK COHOSH BLACK COHOSH COLCHICUM AUTUMNALE BULB COLCHICUM AUTUMNALE BULB SUS SCROFA CONJUNCTIVA SUS SCROFA CONJUNCTIVA SOLANUM DULCAMARA FLOWER SOLANUM DULCAMARA FLOWER VELAFERMIN VELAFERMIN SUS SCROFA UMBILICAL CORD SUS SCROFA UMBILICAL CORD SUS SCROFA ADRENAL GLAND SUS SCROFA ADRENAL GLAND NADIDE NADIDE SODIUM DIETHYL OXALACETATE DIETHYL OXALACETATE NERVE GROWTH FACTOR NERVE GROWTH FACTOR SUS SCROFA PARATHYROID GLAND SUS SCROFA PARATHYROID GLAND SUS SCROFA PLACENTA SUS SCROFA PLACENTA QUINHYDRONE HYDROQUINONE TOXICODENDRON PUBESCENS LEAF TOXICODENDRON PUBESCENS LEAF STRONTIUM CARBONATE STRONTIUM CATION SULFUR SULFUR SUS SCROFA VEIN SUS SCROFA VEIN PRASTERONE PRASTERONE ALCOHOL .ALPHA.-KETOGLUTARIC ACID .ALPHA.-KETOGLUTARIC ACID .ALPHA.-LIPOIC ACID .ALPHA.-LIPOIC ACID"],"pregnancy_or_breast_feeding":["PREGNANCY If pregnant or breast-feeding ask a doctor before use"],"keep_out_of_reach_of_children":["WARNINGS Keep out of reach of children"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL 5USART-ArthroRev06-05-11-18"]},"tags":[{"label":"nadide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Topical","category":"route"},{"label":"Shampoo","category":"form"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"ABDOMINAL DISTENSION","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"GAIT DISTURBANCE","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"HEPATOCELLULAR CARCINOMA","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"MYALGIA","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"ANAPHYLACTIC REACTION","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ARRHYTHMIA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ARTHROPATHY","source":"FDA FAERS","actionTaken":"1 reports"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NADIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:23:49.591824+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Nadide","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:24:02.838444+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:24:11.697392+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:24:01.445108+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NADIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:24:02.231458+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:47.384751+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:47.384794+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:23:47.384805+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:24:03.724486+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3039307/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:24:02.728832+00:00"}},"allNames":"coenzyme i","offLabel":[],"synonyms":["nicotinamide adenine","coenzyme I","nadide","nicotinamide adenine dinucleotide","NAD"],"timeline":[],"aiSummary":"NADIDE, a marketed form of Coenzyme I, is positioned in the market with a mechanism that influences cellular energy production. A key strength is its patent protection, which extends until 2028, providing a period of exclusivity. The primary risk is the lack of specified primary indication and revenue data, which may limit strategic planning and investor confidence.","approvals":[{"date":"","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Coenzyme I","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"Vitamin C [EPC]","explanation":"","oneSentence":"","technicalDetail":"Coenzyme I is a small molecule that interacts with the NAD+ pool, influencing the redox balance and energy metabolism within cells."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Nicotinamide_adenine_dinucleotide","title":"Nicotinamide adenine dinucleotide","extract":"Nicotinamide adenine dinucleotide (NAD) is a coenzyme central to metabolism. Found in all living cells, NAD is called a dinucleotide because it consists of two nucleotides joined through their phosphate groups. One nucleotide contains an adenine nucleobase and the other, nicotinamide. NAD exists in two forms: an oxidized and reduced form, abbreviated as NAD+ and NADH (H for hydrogen), respectively.","wiki_history":"===History===\n*, A history of early enzymology.\n*, a textbook from the 19th century."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4140","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NADIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NADIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Nicotinamide_adenine_dinucleotide","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T14:35:30.865283","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:24:11.698020+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"nadide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07127510","phase":"","title":"Brain NAD in Alzheimer's Disease","status":"RECRUITING","sponsor":"Florida Atlantic University","startDate":"2026-03-18","conditions":["Alzheimer Disease (AD)"],"enrollment":20,"completionDate":"2027-06-01"},{"nctId":"NCT07229638","phase":"PHASE1,PHASE2","title":"A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-02-27","conditions":["Solid Tumor"],"enrollment":70,"completionDate":"2027-06"},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":["Healthspan Improvement","Aging","Longevity"],"enrollment":30,"completionDate":"2026-04"},{"nctId":"NCT06579209","phase":"NA","title":"NAD+ Oral Supplement Pilot Intervention in Adult Females","status":"COMPLETED","sponsor":"University of Rhode Island","startDate":"2024-12-01","conditions":["Cognitive Change","Inflammation","Neurodegenerative Diseases"],"enrollment":53,"completionDate":"2026-02-20"},{"nctId":"NCT06534944","phase":"PHASE1,PHASE2","title":"NAD Supplementation and Vascular Health in PAD","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2023-02-27","conditions":["Peripheral Artery Disease"],"enrollment":8,"completionDate":"2024-12-30"},{"nctId":"NCT04192136","phase":"NA","title":"NAD+ and Exercise in FA","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-09-03","conditions":["Friedreich Ataxia 1"],"enrollment":75,"completionDate":"2025-10-31"},{"nctId":"NCT05040321","phase":"PHASE1,PHASE2","title":"Sirtuin-NAD Activator in Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-12-01","conditions":["Alzheimer's Disease (Incl Subtypes)","Dementia"],"enrollment":22,"completionDate":"2026-04-30"},{"nctId":"NCT03723291","phase":"PHASE1","title":"PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"University College, London","startDate":"2019-09-01","conditions":["Head and Neck Fibrosis"],"enrollment":50,"completionDate":"2022-06-30"},{"nctId":"NCT02064569","phase":"PHASE1,PHASE2","title":"Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients","status":"COMPLETED","sponsor":"GenSight Biologics","startDate":"2014-02-13","conditions":["Leber Hereditary Optic Neuropathy"],"enrollment":19,"completionDate":"2020-06-25"},{"nctId":"NCT07436182","phase":"PHASE4","title":"Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-03-01","conditions":["Mitochondria","Metformin"],"enrollment":176,"completionDate":"2026-06-01"},{"nctId":"NCT07436546","phase":"NA","title":"Prospective Evaluation of Efficacy of Tumescent Steroid Infiltration in Mandibular Third Molar Surgery: a Split Mouth Randomized Study","status":"COMPLETED","sponsor":"Postgraduate Institute of Dental Sciences Rohtak","startDate":"2025-03-23","conditions":["Impacted Third Molar","Impacted Third Molar Tooth","Third Molar Extraction","Third Molar Extraction Surgery"],"enrollment":25,"completionDate":"2025-12-23"},{"nctId":"NCT07428889","phase":"NA","title":"Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement","status":"RECRUITING","sponsor":"Shaklee Corporation","startDate":"2026-02","conditions":["Healthy Adult"],"enrollment":34,"completionDate":"2026-06"},{"nctId":"NCT07394946","phase":"PHASE2","title":"Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Cancer Care Hospital & Research Centre Foundation, Lahore","startDate":"2026-06","conditions":["Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer"],"enrollment":126,"completionDate":"2029-07"},{"nctId":"NCT07144527","phase":"NA","title":"Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults","status":"RECRUITING","sponsor":"Scott Silveira","startDate":"2026-02-21","conditions":["Aging","Frailty","Exercise Tolerance","Healthy Male and Female Subjects"],"enrollment":40,"completionDate":"2027-01-01"},{"nctId":"NCT06533345","phase":"NA","title":"VCOM Pain Free Research Collaborative","status":"RECRUITING","sponsor":"Edward Via Virginia College of Osteopathic Medicine","startDate":"2024-08-30","conditions":["Chronic Pain"],"enrollment":120,"completionDate":"2027-08-01"},{"nctId":"NCT05488483","phase":"","title":"A Study of Tumor Imaging With Multispectral Optoacoustic Tomography","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-07-27","conditions":["Breast Cancer","Melanoma"],"enrollment":12,"completionDate":"2026-07-27"},{"nctId":"NCT06815991","phase":"PHASE1","title":"Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults","status":"RECRUITING","sponsor":"Metro International Biotech, LLC","startDate":"2025-02-11","conditions":["Healthy Adults"],"enrollment":32,"completionDate":"2027-03"},{"nctId":"NCT07416786","phase":"NA","title":"Validation of NAD+ Measurements for Human Clinical Studies","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-04-01","conditions":["Healthy Adults"],"enrollment":48,"completionDate":"2028-07-31"},{"nctId":"NCT06627868","phase":"NA","title":"Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue","status":"RECRUITING","sponsor":"University of Turku","startDate":"2024-11-20","conditions":["Obesity, Abdominal"],"enrollment":68,"completionDate":"2027-08-31"},{"nctId":"NCT05759468","phase":"PHASE2","title":"NAD Augmentation in Diabetes Kidney Disease","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-04-13","conditions":["Type2diabetes","Diabetic Kidney Disease"],"enrollment":140,"completionDate":"2027-03-31"},{"nctId":"NCT06032923","phase":"PHASE1,PHASE2","title":"Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2024-03-13","conditions":["Systemic Lupus Erythematosus (Sle)"],"enrollment":78,"completionDate":"2028-08-01"},{"nctId":"NCT06983730","phase":"EARLY_PHASE1","title":"The Kidney's Response to Exercise in Heat, and the Impact of Vitamin B3 on This Response","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2026-01-26","conditions":["Heat Strain","Healthy Volunteer Study","Kidney Dysfunction"],"enrollment":28,"completionDate":"2028-06"},{"nctId":"NCT02649985","phase":"PHASE1,PHASE2","title":"PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2016-05-02","conditions":["Multiple Sclerosis","Alzheimer's Disease"],"enrollment":250,"completionDate":"2027-12-31"},{"nctId":"NCT04914845","phase":"PHASE1","title":"KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-08-27","conditions":["Acute Myeloid Leukemia","Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory"],"enrollment":16,"completionDate":"2025-10-22"},{"nctId":"NCT05561738","phase":"NA","title":"Nicotinamide Riboside in Ulcerative Colitis","status":"RECRUITING","sponsor":"University of Pittsburgh","startDate":"2024-02-28","conditions":["Ulcerative Colitis"],"enrollment":40,"completionDate":"2026-06-30"},{"nctId":"NCT07336836","phase":"EARLY_PHASE1","title":"Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort","status":"COMPLETED","sponsor":"BioNADrx Holdings, Inc. Bryleos","startDate":"2022-02-23","conditions":["Health Adult Subjects","Healthy Participants"],"enrollment":60,"completionDate":"2022-06-04"},{"nctId":"NCT07328100","phase":"NA","title":"Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2026-01-16","conditions":["Vascular Aging","NAD"],"enrollment":60,"completionDate":"2027-12-31"},{"nctId":"NCT07307872","phase":"","title":"A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease","status":"COMPLETED","sponsor":"Amoneta Diagnostics SAS","startDate":"2017-03-23","conditions":["Alzheimer's Disease (AD)","Neurodegenerative Disease","Dementia","Frontotemporal Dementia (FTD)"],"enrollment":150,"completionDate":"2018-12-01"},{"nctId":"NCT07299279","phase":"NA","title":"Movement Improves Brain Health and Cognition in Parkinson's Disease","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-06-09","conditions":["Parkinson Disease"],"enrollment":150,"completionDate":"2028-04-30"},{"nctId":"NCT03993171","phase":"PHASE2","title":"31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.","status":"COMPLETED","sponsor":"Clene Nanomedicine","startDate":"2019-12-19","conditions":["Multiple Sclerosis"],"enrollment":33,"completionDate":"2025-07-31"},{"nctId":"NCT07284225","phase":"NA","title":"Acute Effects of Nicotinamide Riboside on Polysomnography-Measured Sleep Structure in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-12-20","conditions":["Healthy Volunteers"],"enrollment":20,"completionDate":"2026-12-30"},{"nctId":"NCT07255378","phase":"","title":"Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication","status":"RECRUITING","sponsor":"Jamil Cedeño Mora","startDate":"2025-10-01","conditions":["Septic Shock"],"enrollment":1200,"completionDate":"2028-01-01"},{"nctId":"NCT07278492","phase":"PHASE1","title":"NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-04-01","conditions":["Down Syndrome (DS)"],"enrollment":24,"completionDate":"2028-06-30"},{"nctId":"NCT06465381","phase":"NA","title":"Safety Planning and Cognitive Behavioral Therapy for Adolescent Suicide Prevention in Mozambique","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-09-01","conditions":["Suicide Prevention"],"enrollment":2100,"completionDate":"2028-12-01"},{"nctId":"NCT05194397","phase":"PHASE2","title":"Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-02-23","conditions":["Lymphoblastic Leukemia","Cancer Survivors","Aplastic Anemia","Myelodysplastic Syndromes","Myeloid Leukemia"],"enrollment":80,"completionDate":"2026-06-30"},{"nctId":"NCT05617508","phase":"PHASE2","title":"N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2022-11-22","conditions":["Alzheimer Disease","Dementia"],"enrollment":80,"completionDate":"2025-06-05"},{"nctId":"NCT05690971","phase":"NA","title":"Psychosocial Mobile App for Chronic Graft-Versus-Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-01-23","conditions":["Chronic Graft-Versus-Host Disease","Allogeneic Stem Cell Transplant"],"enrollment":120,"completionDate":"2026-06-01"},{"nctId":"NCT04661995","phase":"NA","title":"Notched Noise Therapy for Suppression of Tinnitus","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-03-01","conditions":["Tinnitus","Notched Noise Therapy"],"enrollment":108,"completionDate":"2026-05-31"},{"nctId":"NCT07203131","phase":"NA","title":"Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Care (NI-AKI)","status":"RECRUITING","sponsor":"Ramsay Générale de Santé","startDate":"2025-03-17","conditions":["Acute Renal Insufficiency","NAD"],"enrollment":150,"completionDate":"2025-12-05"},{"nctId":"NCT03568968","phase":"PHASE3","title":"A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2020-05-06","conditions":["Parkinson Disease"],"enrollment":410,"completionDate":"2025-06-17"},{"nctId":"NCT07178964","phase":"NA","title":"POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS","status":"NOT_YET_RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-10-01","conditions":["Hypertension Arterial","Kidney Transplant"],"enrollment":80,"completionDate":"2026-09-30"},{"nctId":"NCT06971224","phase":"PHASE2","title":"NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2025-10-13","conditions":["Sleep"],"enrollment":16,"completionDate":"2026-06-01"},{"nctId":"NCT06866236","phase":"PHASE2,PHASE3","title":"Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression","status":"NOT_YET_RECRUITING","sponsor":"Ebima Clifford Okundaye","startDate":"2025-10","conditions":["Chronic Kidney Diseases","Acute Kidney Injury","Kidney Failure"],"enrollment":3000,"completionDate":"2027-07"},{"nctId":"NCT06948292","phase":"PHASE2","title":"Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics","status":"COMPLETED","sponsor":"Ebima Clifford Okundaye","startDate":"2023-03-01","conditions":["Chronic Kidney Disease Stages 3-5","Diabetic Kidney Disease","Hypertensive Kidney Disease"],"enrollment":127,"completionDate":"2024-10-30"},{"nctId":"NCT06128538","phase":"NA","title":"Implementing Group Battlefield Acupuncture in CCRCs for the Treatment of Chronic Lower Back Pain","status":"COMPLETED","sponsor":"Korey Kennelty","startDate":"2024-10-30","conditions":["Pain, Back"],"enrollment":11,"completionDate":"2025-08-15"},{"nctId":"NCT05500170","phase":"NA","title":"Benefits of Nicotinamide Riboside Upon Cognition and Sleep","status":"RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2023-04-04","conditions":["Cognitive Impairment","Sleep Quality"],"enrollment":50,"completionDate":"2027-08-30"},{"nctId":"NCT07132801","phase":"NA","title":"Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels","status":"NOT_YET_RECRUITING","sponsor":"Qualia Life Sciences","startDate":"2025-10-13","conditions":["NAD","NAD+ Levels in the Blood"],"enrollment":180,"completionDate":"2025-12-15"},{"nctId":"NCT06776510","phase":"PHASE1,PHASE2","title":"A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-15","conditions":["Immune Thrombocytopenia","Treatment"],"enrollment":20,"completionDate":"2026-03-01"},{"nctId":"NCT04809974","phase":"PHASE4","title":"Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-08-28","conditions":["Covid19","Sequelae of; Infection","Cognitive Symptom"],"enrollment":72,"completionDate":"2024-02-23"},{"nctId":"NCT05528848","phase":"PHASE1","title":"Multi-System Analysis of Opioid Receptor Binding","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-09-20","conditions":["Healthy","Opioid Use Disorder"],"enrollment":60,"completionDate":"2026-09"},{"nctId":"NCT06162741","phase":"NA","title":"Type I Hybrid Effectiveness-Implementation Trial of Primary Care Brief Mindfulness Training for Veterans","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-08-19","conditions":["Post Traumatic Stress Disorder (PTSD)","Depression","Anxiety"],"enrollment":300,"completionDate":"2027-12-31"},{"nctId":"NCT05243290","phase":"NA","title":"Nicotinamide Riboside Clinical Trial for GWI","status":"RECRUITING","sponsor":"Roskamp Institute Inc.","startDate":"2022-04-13","conditions":["Gulf War Illness"],"enrollment":52,"completionDate":"2025-12-31"},{"nctId":"NCT07073352","phase":"NA","title":"ACEs, SIRT1, and Premature Vascular Aging in Humans","status":"RECRUITING","sponsor":"Nathaniel Jenkins","startDate":"2025-03-27","conditions":["Adverse Childhood Experiences","Endothelial Dysfunction"],"enrollment":30,"completionDate":"2027-06-30"},{"nctId":"NCT06425042","phase":"NA","title":"Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity","status":"RECRUITING","sponsor":"Finis Terrae University","startDate":"2024-03-01","conditions":["Healthy Aging","Lifestyle-related Condition","Metabolic Diseases"],"enrollment":28,"completionDate":"2026-03"},{"nctId":"NCT04965987","phase":"PHASE1","title":"Oxaloacetate in Myasthenia Gravis","status":"WITHDRAWN","sponsor":"University of Kansas Medical Center","startDate":"2025-08","conditions":["Myasthenia Gravis"],"enrollment":0,"completionDate":"2026-12"},{"nctId":"NCT05589766","phase":"PHASE2","title":"N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2023-01-23","conditions":["Parkinson Disease"],"enrollment":81,"completionDate":"2025-04-22"},{"nctId":"NCT06991712","phase":"PHASE2","title":"Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients","status":"RECRUITING","sponsor":"Christopher Kai Shun Leung","startDate":"2025-05-19","conditions":["Glaucoma"],"enrollment":138,"completionDate":"2026-12-31"},{"nctId":"NCT04784767","phase":"PHASE1","title":"PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2021-04-05","conditions":["SARS-CoV-2 Infection"],"enrollment":29,"completionDate":"2023-10-30"},{"nctId":"NCT05366088","phase":"NA","title":"RCT of MBCT vs HEP for Late-Life Depression","status":"TERMINATED","sponsor":"Lady Davis Institute","startDate":"2023-10-01","conditions":["Depression in Old Age","Quality of Life"],"enrollment":100,"completionDate":"2025-05-01"},{"nctId":"NCT06190236","phase":"NA","title":"Integration of Neurofunctional Phenotyping Into Investigation of CBT4CBT for AUD","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2024-04-10","conditions":["Alcohol Abuse","Alcohol Use Disorder"],"enrollment":248,"completionDate":"2025-04-22"},{"nctId":"NCT07006194","phase":"NA","title":"Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)","status":"NOT_YET_RECRUITING","sponsor":"Università degli Studi 'G. d'Annunzio' Chieti e Pescara","startDate":"2025-10-01","conditions":["Glaucoma"],"enrollment":360,"completionDate":"2026-12-31"},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":["Acute Lymphoblastic Leukemia (ALL)"],"enrollment":141,"completionDate":"2024-06-28"},{"nctId":"NCT05405309","phase":"PHASE1,PHASE2","title":"RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"University of Utah","startDate":"2022-09-23","conditions":["Chronic Lymphocytic Leukemia"],"enrollment":5,"completionDate":"2025-01-10"},{"nctId":"NCT02205762","phase":"PHASE2,PHASE3","title":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"North American Consortium for Histiocytosis","startDate":"2016-11-02","conditions":["Langerhans Cell Histiocytosis"],"enrollment":1400,"completionDate":"2026-07"},{"nctId":"NCT06966583","phase":"PHASE1","title":"NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-05-01","conditions":["Solid Tumor","Non Small Cell Lung Cancer"],"enrollment":20,"completionDate":"2027-11-30"},{"nctId":"NCT06965829","phase":"PHASE2","title":"The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-07-01","conditions":["Esophageal Cancer Stage III"],"enrollment":40,"completionDate":"2028-07-01"},{"nctId":"NCT06882096","phase":"PHASE1","title":"Tracing the Metabolic Flux of Orally Administered NAD+ Precursors","status":"RECRUITING","sponsor":"Metro International Biotech, LLC","startDate":"2025-04-28","conditions":["Healthy Adults"],"enrollment":32,"completionDate":"2027-06"},{"nctId":"NCT06303128","phase":"PHASE3","title":"Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge","status":"RECRUITING","sponsor":"James Tarbox, MD","startDate":"2024-02-03","conditions":["Penicillin Allergy"],"enrollment":380,"completionDate":"2026-12"},{"nctId":"NCT06950463","phase":"NA","title":"EFFECT OF CIRCUIT TRAINING ON BONE MINERAL DENSITY IN POST MENOPAUSAL PERIOD","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-01-01","conditions":["Post Menopausal","Osteoporosis"],"enrollment":44,"completionDate":"2025-07-01"},{"nctId":"NCT05517122","phase":"NA","title":"Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults","status":"COMPLETED","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2022-07-12","conditions":["Healthy"],"enrollment":68,"completionDate":"2022-11-24"},{"nctId":"NCT06941233","phase":"NA","title":"Our Peers - Empowerment and Navigational Support - Community Living: Remote Peer Navigator Intervention for Adults With Newly Acquired Disabilities Transitioning to Community Living (OP-ENS -CL)","status":"NOT_YET_RECRUITING","sponsor":"Susan Magasi","startDate":"2025-06","conditions":["Disabled Persons"],"enrollment":100,"completionDate":"2027-08"},{"nctId":"NCT06847126","phase":"PHASE3","title":"Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2025-02-25","conditions":["Liver Abscess"],"enrollment":220,"completionDate":"2026-06-30"},{"nctId":"NCT06919328","phase":"NA","title":"Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+","status":"RECRUITING","sponsor":"Nutraceuticals Research Institute","startDate":"2024-10-31","conditions":["Healthy Aging"],"enrollment":70,"completionDate":"2025-06-30"},{"nctId":"NCT03482167","phase":"PHASE1,PHASE2","title":"NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment","status":"COMPLETED","sponsor":"University of Delaware","startDate":"2019-03-20","conditions":["Mild Cognitive Impairment"],"enrollment":64,"completionDate":"2024-01-22"},{"nctId":"NCT04049747","phase":"NA","title":"Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-12-11","conditions":["Prostate Cancer","Non-metastatic Prostate Cancer","Prostate Adenocarcinoma"],"enrollment":100,"completionDate":"2023-03-20"},{"nctId":"NCT05416658","phase":"NA","title":"Shared Decision Making for Antipsychotic Medications","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-01-01","conditions":["Schizophrenia","Schizoaffective Disorder","Schizophreniform Disorders","Delusional Disorder","Other Specified Schizophrenia Spectrum and Other Psychotic Disorder"],"enrollment":120,"completionDate":"2026-06-30"},{"nctId":"NCT06853743","phase":"PHASE2","title":"The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2025-03-18","conditions":["Huntington Disease"],"enrollment":120,"completionDate":"2029-03"},{"nctId":"NCT04905446","phase":"NA","title":"Measurement of NAD+ Synthesis in Human Skeletal Muscle","status":"COMPLETED","sponsor":"AdventHealth Translational Research Institute","startDate":"2021-09-10","conditions":["Skeletal Muscle"],"enrollment":15,"completionDate":"2024-12-20"},{"nctId":"NCT06726369","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2024-12-12","conditions":["Advanced Solid Tumors"],"enrollment":90,"completionDate":"2029-12-31"},{"nctId":"NCT04750616","phase":"PHASE2","title":"NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial","status":"RECRUITING","sponsor":"Kaiser Permanente","startDate":"2021-09-13","conditions":["Ischemia Reperfusion Injury","Myocardial Injury","Acute Kidney Injury"],"enrollment":304,"completionDate":"2025-06-30"},{"nctId":"NCT06071832","phase":"NA","title":"Using Structured Video Chat to Improve Relationships Between Young Children and Remote Grandparents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lafayette College","startDate":"2022-11-01","conditions":["Child Development","Family Members","Grandparents"],"enrollment":540,"completionDate":"2025-09-01"},{"nctId":"NCT03818802","phase":"NA","title":"Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-09-16","conditions":["Healthy Elderly Volunteers"],"enrollment":53,"completionDate":"2024-11-08"},{"nctId":"NCT03821623","phase":"PHASE2","title":"Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults","status":"RECRUITING","sponsor":"Douglas Seals","startDate":"2019-05-10","conditions":["Hypertension","Aging"],"enrollment":118,"completionDate":"2025-06-01"},{"nctId":"NCT06812416","phase":"NA","title":"Effectiveness of Qualia NAD+ Supplementation on NAD Levels","status":"COMPLETED","sponsor":"Qualia Life Sciences","startDate":"2023-10-24","conditions":["Intracellular NAD+ Levels"],"enrollment":92,"completionDate":"2024-03-11"},{"nctId":"NCT06810089","phase":"","title":"Examination of Lacrimal Sac and Nasal Mucosa Preparations Taken in Dacryocystorhinostomy Surgery of Patients With Nasolacrimal Duct Obstruction and Comparison of Clinical Groups With Each Other","status":"COMPLETED","sponsor":"Uludag University","startDate":"2023-05-15","conditions":["Dacryocystitis","Dacryocystitis; Chronic","Dacryocystorhinostomy","Epiphora","Nasolacrimal Duct Obstruction","Surfactant","Mucin","Lacrimal Sac Mucosa","Nasal Mucosa"],"enrollment":78,"completionDate":"2024-04-30"},{"nctId":"NCT06802679","phase":"PHASE4","title":"Comparison of Standard Versus High Dose Urokinase for Dysfunctional Tunneled Dialysis Catheters in Haemodialysis Patients: a Randomized Controlled Trial","status":"COMPLETED","sponsor":"National Healthcare Group, Singapore","startDate":"2020-10-01","conditions":["Hemodialysis","Thrombolytic Therapy","Dialysis Access Dysfunction","Randomised Controlled Trial","End Stage Renal Disease (ESRD)"],"enrollment":44,"completionDate":"2025-01-27"},{"nctId":"NCT06208527","phase":"PHASE2","title":"The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2025-01","conditions":["Frailty","Frail Elderly Syndrome","Frailty Syndrome","Aging"],"enrollment":100,"completionDate":"2030-12"},{"nctId":"NCT05698771","phase":"PHASE1","title":"NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2022-09-17","conditions":["Healthy"],"enrollment":12,"completionDate":"2024-03-04"},{"nctId":"NCT06162013","phase":"PHASE2","title":"The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2024-03-05","conditions":["Progressive Supranuclear Palsy","Multiple System Atrophy","Corticobasal Syndrome"],"enrollment":330,"completionDate":"2028-12"},{"nctId":"NCT02962076","phase":"EARLY_PHASE1","title":"Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia","status":"TERMINATED","sponsor":"Khaled Awad, MD","startDate":"2020-09-21","conditions":["Ventricular Tachycardia"],"enrollment":11,"completionDate":"2024-10-31"},{"nctId":"NCT06200779","phase":"PHASE4","title":"Tailored Vs. Empirical Helicobacter Pylori Infection Treatment","status":"NOT_YET_RECRUITING","sponsor":"Manuel Coelho da Rocha","startDate":"2025-09","conditions":["Helicobacter Pylori Infection"],"enrollment":160,"completionDate":"2026-12"},{"nctId":"NCT06558253","phase":"PHASE1","title":"The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-11-29","conditions":["Hematopoietic Recovery"],"enrollment":12,"completionDate":"2026-09-30"},{"nctId":"NCT03746366","phase":"EARLY_PHASE1","title":"[C-11]PiB PET Imaging in Alcohol Use Disorders","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2018-12-01","conditions":["Alcohol Use Disorder"],"enrollment":39,"completionDate":"2020-07-01"},{"nctId":"NCT03865927","phase":"PHASE2","title":"GKT137831 in IPF Patients with Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-09-07","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":58,"completionDate":"2024-11-30"},{"nctId":"NCT06389825","phase":"NA","title":"Unravelling the Impact of Diet on Cardiovascular Health in Treated Heterozygous Familial Hypercholesterolemia.","status":"COMPLETED","sponsor":"Laval University","startDate":"2024-04-01","conditions":["Familial Hypercholesterolemia","Nutrition, Healthy","Cholesterol, Elevated"],"enrollment":11,"completionDate":"2024-06-30"},{"nctId":"NCT05229705","phase":"NA","title":"Exercise in Older Adults at Risk for Type 2 Diabetes","status":"COMPLETED","sponsor":"Western University, Canada","startDate":"2022-09-23","conditions":["Cognitive Change"],"enrollment":60,"completionDate":"2024-06-05"},{"nctId":"NCT06429215","phase":"NA","title":"REducing the Risk of COgnitive DEcline ad Dementia in Patients With Subjective Cognitive Decline Through an Immersive Virtual Reality and Telemedicine-based Multi-component Intervention: the SCD-ReCODED Study","status":"RECRUITING","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2024-07-01","conditions":["Subjective Cognitive Decline"],"enrollment":75,"completionDate":"2025-12"},{"nctId":"NCT03727646","phase":"EARLY_PHASE1","title":"Nicotinamide Riboside in LVAD Recipients","status":"COMPLETED","sponsor":"University of Washington","startDate":"2018-09-26","conditions":["Heart Failure，Congestive","Heart Failure New York Heart Association Class IV","Mitochondrial Alteration"],"enrollment":5,"completionDate":"2018-11-26"},{"nctId":"NCT06590844","phase":"PHASE4","title":"\"cindilizumab + Bevacizumab + Coenzyme I for Injection\" in Unresectable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2023-12-19","conditions":["Unresectable Hepatocellular Carcinoma"],"enrollment":37,"completionDate":"2026-03"},{"nctId":"NCT05038488","phase":"PHASE2","title":"Phase 2a MIB-626 vs. Placebo COVID-19","status":"COMPLETED","sponsor":"Metro International Biotech, LLC","startDate":"2021-10-26","conditions":["Covid19","Stage 1 Acute Kidney Injury"],"enrollment":42,"completionDate":"2023-08-17"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Shampoo","formulations":[{"form":"SHAMPOO","route":"TOPICAL","productName":"Bonogen Plushair care shampoo"},{"form":"SHAMPOO","route":"TOPICAL","productName":"Bonogenhair care shampoo"},{"form":"SHAMPOO","route":"TOPICAL","productName":"Born Hair"}]},"crossReferences":{"NUI":"N0000170823","NDDF":"008958","UNII":"0U46U6E8UK","CHEBI":"CHEBI:44215","INN_ID":"2371","RXNORM":"1044975","UMLSCUI":"C0027270","chemblId":"CHEMBL3039307","ChEMBL_ID":"CHEMBL1234613","KEGG_DRUG":"D00002","DRUGBANK_ID":"DB14128","PDB_CHEM_ID":" NAD","PUBCHEM_CID":"5892","IUPHAR_LIGAND_ID":"2451","MESH_DESCRIPTOR_UI":"D009243"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":6,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[{"date":"2023","pmid":"37396659","title":"Identifying potential drug-target interactions based on ensemble deep learning.","journal":"Frontiers in aging neuroscience"},{"date":"2022","pmid":"35789829","title":"Drug repurposing against main protease and RNA-dependent RNA polymerase of SARS-CoV-2 using molecular docking, MM-GBSA calculations and molecular dynamics.","journal":"Structural chemistry"},{"date":"2021 Oct 2","pmid":"34601658","title":"Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.","journal":"Journal of molecular modeling"},{"date":"2021 Mar","pmid":"33352458","title":"Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study.","journal":"Computers in biology and medicine"},{"date":"1979 Aug","pmid":"480166","title":"Improved spectrophotometric determination of glycerol and its comparison with an enzymatic method.","journal":"Journal of pharmaceutical sciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:24:11.698020+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}